[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Cummings, 2011 - Google Patents

Alzheimer's disease clinical trials: changing the paradigm

Cummings, 2011

Document ID
4084242653901201283
Author
Cummings J
Publication year
Publication venue
Current psychiatry reports

External Links

Snippet

Alzheimer's disease (AD) is rapidly becoming a public health emergency; there are currently 35 million victims worldwide, with a projected growth to more than 100 million by 2050 if means to delay the onset, slow the progression, or ameliorate the symptoms are not found …
Continue reading at link.springer.com (other versions)

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2821Alzheimer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2835Movement disorders, e.g. Parkinson, Huntington, Tourette
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids

Similar Documents

Publication Publication Date Title
Self et al. Emerging diagnostics and therapeutics for Alzheimer disease
Frisoni et al. The probabilistic model of Alzheimer disease: the amyloid hypothesis revised
Ringman et al. Genetic heterogeneity in Alzheimer disease and implications for treatment strategies
Takahashi et al. Opposing effects of progranulin deficiency on amyloid and tau pathologies via microglial TYROBP network
Mufson et al. Nerve growth factor pathobiology during the progression of Alzheimer’s disease
Stanley et al. Changes in insulin and insulin signaling in Alzheimer’s disease: cause or consequence?
Imbimbo et al. Pathophysiology of Alzheimer's disease
Murray et al. Clinicopathologic assessment and imaging of tauopathies in neurodegenerative dementias
Yu et al. Apolipoprotein E in Alzheimer's disease: an update
Sabuncu et al. The association between a polygenic Alzheimer score and cortical thickness in clinically normal subjects
Rhinn et al. Integrative genomics identifies APOE ε4 effectors in Alzheimer's disease
Coarelli et al. Recent advances in understanding dominant spinocerebellar ataxias from clinical and genetic points of view
Kulstad et al. Differential modulation of plasma β-amyloid by insulin in patients with Alzheimer disease
Liao et al. Murine versus human apolipoprotein E4: differential facilitation of and co-localization in cerebral amyloid angiopathy and amyloid plaques in APP transgenic mouse models
Desikan et al. Heart fatty acid binding protein and Aβ-associated Alzheimer’s neurodegeneration
Guest et al. Early diagnosis and targeted treatment strategy for improved therapeutic outcomes in Alzheimer’s disease
Sun et al. APOE ε4 carriers may undergo synaptic damage conferring risk of Alzheimer's disease
Tong et al. Effects of single doses of avagacestat (BMS-708163) on cerebrospinal fluid Aβ levels in healthy young men
Sohn et al. ApoE4 attenuates autophagy via FoxO3a repression in the brain
Young et al. APOE effects on regional tau in preclinical Alzheimer’s disease
Li et al. Genome-wide association and interaction studies of CSF T-tau/Aβ42 ratio in ADNI cohort
Koran et al. Genetic interactions found between calcium channel genes modulate amyloid load measured by positron emission tomography
Krance et al. Reciprocal predictive relationships between amyloid and tau biomarkers in Alzheimer's disease progression: an empirical model
Keene et al. Epidemiology, pathology, and pathogenesis of Alzheimer disease
Kerchner et al. The role of aging in Alzheimer’s disease